1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008; 372:657–68.
Article
2. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991; 615:125–7.
Article
3. van Slegtenhorst M, de Hoogt R, Hermans C. . Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997; 277:805–8.
4. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16 Cell. 1993; 75:1305–15.
5. Vogt H. Zur diagnostik der tuberosen sclerose. Z Erforsch Benhandl Fugendl Schwachsinns. 1908; 2:1–16.
6. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998; 13:624–8.
Article
7. Rowley SA, O'Callaghan FJ, Osborne JP. Ophthalmic manifes-tations of tuberous sclerosis: a population based study. Br J Ophthalmol. 2001; 85:420–3.
Article
8. Kiribuchi K, Uchida Y, Fukuyama Y, Maruyama H. High incidence of fundus hamartomas and clinical significance of a fundus score in tuberous sclerosis. Brain Dev. 1986; 8:509–17.
Article
9. Töteberg-Harms M, Sturm V, Sel S. . Retinal astrocytomas: long-term follow-up. Klin Monbl Augenheilkd. 2011; 228:337–9.
Article
10. Gass JDM. Stereoscopic atlas of macular disease. Diagnosis and treatment. 1st ed.St. Louis: Mosby;1997; 836–43.
11. Lagos JC, Gomez MR. Tuberous sclerosis: Reappraisal of a clin-ical entity. Mayo Clin Proc. 1967; 42:26–49.
12. Nyboer JH, Robertson DM, Gomez MR. Retinal lesions in tuber-ous sclerosis. Arch Ophthal. 1976; 94:1277–80.
Article
13. Yoon DK. A case of tuberous sclerosis. J Korean Ophthalmol Soc. 1974; 15:68–71.
14. Kim JH, Shin HH. Two cases of tuberous sclerosis. J Korean Ophthalmol Soc. 1982; 23:477–81.
15. Kwon OW, Kim YW. A case of tuberous sclerosis. J Korean Ophthalmol Soc. 1983; 24:645–9.
16. Yoo KH, Oum BS. Two cases of tuberous sclerosis. J Korean Ophthalmol Soc. 1987; 28:877–83.
17. Kim SM, Hahn YH, Kim SD. Two cases of tuberous sclerosis. J Korean Ophthalmol Soc. 1988; 29:1141–5.
18. Ku YJ, Kim EA, Han YB. A case of tuberous sclerosis. J Korean Ophthalmol Soc. 1995; 36:355–60.
19. Ji JY, Lee JH, Choi WS. A case of bilateral tuberous sclerosis. J Korean Ophthalmol Soc. 1996; 37:203–9.
20. Lee JH, Han KS, Han YB. One case of tuberous sclerosis. J Korean Ophthalmol Soc. 1999; 40:2337–42.
21. La TY, Kim CW, Lee YS, Kim MH. A case of retinal astrocytic ha-martoma causing blindness in tuberous sclerosis. J Korean Ophthalmol Soc. 1999; 40:1421–6.
22. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med. 1996; 334:1583–90.
Article
23. Ben-Menachem E. Vigabatrin. Epilepsia. 1995; 36:Suppl 2. S95–104.
Article
24. Maguire MJ, Hemming K, Wild JM. . Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010; 51:2423–31.
Article
25. Roubertie A, Bellet H, Echenne B. Vigabatrin-associated retinal cone system dysfunction. Neurology. 1998; 51:1779–81.
Article
26. Miller NR, Johnson MA, Paul SR. . Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology. 1999; 53:2082–7.
Article
27. Lawthom C, Smith PE, Wild JM. Nasal retinal nerve fiber layer at-tenuation: a biomarker for vigabatrin toxicity. Ophthalmology. 2009; 116:565–71.
Article
28. Clayton LM, Devile M, Punte T. . Patterns of peripapillary reti-nal nerve fiber layer thinning in vigabatrin-exposed individuals. Ophthalmology. 2012; 119:2152–60.
Article
29. Roh S, Noecker RJ, Schuman JS. . Effect of optic nerve head drusen on nerve fiber layer thickness. Ophthalmology. 1998; 105:878–85.
30. Savino PJ, Glaser JS, Rosenberg MA. A clinical analysis of pseudopapilledema. II. Visual field defects. Arch Ophthalmol. 1979; 97:71–5.
Article
31. Sarkies NJ, Sanders MD. Optic disc drusen and episodic visual loss. Br J Ophthalmol. 1987; 71:537–9.
Article
32. Shields CL, Benevides R, Materin MA, Shields JA. Optical coher-ence tomography of retinal astrocytic hamartoma in 15 cases. Ophthalmology. 2006; 113:1553–7.
Article